Home > Medicine > Other > Volume-4 > Issue-2 > Progress of Cancer Precision Medical by Approval of Medical Insurance of Cancer Gene Panel Test

Progress of Cancer Precision Medical by Approval of Medical Insurance of Cancer Gene Panel Test

Call for Papers

Volume-6 | Issue-5

Last date : 27-Aug-2022

Best International Journal
Open Access | Peer Reviewed | Best International Journal | Indexing & IF | 24*7 Support | Dedicated Qualified Team | Rapid Publication Process | International Editor, Reviewer Board | Attractive User Interface with Easy Navigation

Journal Type : Open Access

Processing Charges : 700/- INR Only OR 25 USD (for foreign users)

First Update : Within 7 Days after submittion

Submit Paper Online

For Author

Research Area



Progress of Cancer Precision Medical by Approval of Medical Insurance of Cancer Gene Panel Test


Takuma Hayashi | Takashi Ura | Ikuo Konishi



Takuma Hayashi | Takashi Ura | Ikuo Konishi "Progress of Cancer Precision Medical by Approval of Medical Insurance of Cancer Gene Panel Test" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-4 | Issue-2, February 2020, pp.53-55, URL: https://www.ijtsrd.com/papers/ijtsrd29914.pdf

Public medical insurance is applied to the genetic testing system of "Cancer genomic medicine", which chooses the most appropriate drug from the result of examining the gene mutation of the patient's cancer cell. The curtain of cancer genomic medicine era was opened. Healthcare professionals want to understand the possibilities and limitations of testing and to steadily develop this medical technology. The testing equipment are the "OncoGuide™ NCC oncopanel system" developed by the National Cancer Research Center and the "Foundation One CDx" produced by Chugai Pharmaceutical Company. In each case, more than 100 types of cancer-related gene mutations can be examined at one time. The number of patients eligible for genome medical treatment is estimated to be approximately 26,000 for patients with solid and rare cancers without standard treatment. Until now, it cost several hundred thousand yen for the patient. Patients who are said to have "no cure" are tested to a small degree, are looking for anti-cancer drugs that could be used. With public health insurance, a series of tests cost 560,000 yen, for people under the age of 70 with average income, medical expenses are about 80,000 yen. It will be able to receive examinations widely at less than 200 medical institutions nationwide. This new cancer treatment gives new hope to patients with cancer. However, patients with cancer should not have excessive expectations. It is necessary to keep in mind that there is a limit to clinical cancer treatment.

precision medicine, cancer genomic medicine, anti-cancer drugs


IJTSRD29914
Volume-4 | Issue-2, February 2020
53-55
IJTSRD | www.ijtsrd.com | E-ISSN 2456-6470
Copyright © 2019 by author(s) and International Journal of Trend in Scientific Research and Development Journal. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0) (http://creativecommons.org/licenses/by/4.0)

International Journal of Trend in Scientific Research and Development - IJTSRD having online ISSN 2456-6470. IJTSRD is a leading Open Access, Peer-Reviewed International Journal which provides rapid publication of your research articles and aims to promote the theory and practice along with knowledge sharing between researchers, developers, engineers, students, and practitioners working in and around the world in many areas like Sciences, Technology, Innovation, Engineering, Agriculture, Management and many more and it is recommended by all Universities, review articles and short communications in all subjects. IJTSRD running an International Journal who are proving quality publication of peer reviewed and refereed international journals from diverse fields that emphasizes new research, development and their applications. IJTSRD provides an online access to exchange your research work, technical notes & surveying results among professionals throughout the world in e-journals. IJTSRD is a fastest growing and dynamic professional organization. The aim of this organization is to provide access not only to world class research resources, but through its professionals aim to bring in a significant transformation in the real of open access journals and online publishing.

Thomson Reuters
Google Scholer
Academia.edu

ResearchBib
Scribd.com
archive

PdfSR
issuu
Slideshare

WorldJournalAlerts
Twitter
Linkedin